Alexander Spira, MD, PhD, FACP
Co-Director, VCS Research Institute, Director, Thoracic and Phase I Program, Clinical Assistant Professor, Johns Hopkins
Dr. Alexander Spira earned his medical degree from the New York University School of Medicine. He then went on to complete his internship and residency at the Hospital of the University of Pennsylvania, and his medical oncology fellowship at Johns Hopkins Hospital. During his training, Dr. Spira was granted many awards and honors, and he completed several specialized fellowship programs. Among these honors were the National Institutes of Health Medical Scientist Training Program Fellowship (1990-1997), Merck Corporation Scholarship (1995-1995), Pediatric AIDS Foundation Fellowship (1993- 1995) and Harvard University Scholarship (1987-1990). Dr. Spira has also received his PhD from the New York School of Arts and Sciences.
As Director of the Virginia Cancer Specialists (VCS) Research Institute and the Phase I Trial Program, Dr. Spira is actively involved in advancing medicine and offering targeted treatment options for patients. Although his research interests are numerous, Dr. Spira particularly enjoys studying immunotherapy, personalized medicine, GI, thoracic and lung cancer and sarcomas. Dr. Spira is also Co-Chair of the USOncology Thoracic Oncology Committee, Chair of the USOncology Research Executive Committee, and member of the USOncology National Policy Board Executive Committee. Dr. Spira is a faculty member at Johns Hopkins School of Medicine, and serves as Assistant Professor of Oncology.
Throughout his career, Dr. Spira has been recognized as a Top Doctor in Northern Virginia Magazine and Washingtonian magazine for multiple years. In 2014, he received the prestigious “Castle Connolly America’s Top Doctor” award. In his spare time, Dr. Spira enjoys spending time with his family, coaching children’s sports, cycling, and cheering on his favorite New York sports teams.
Financial relationships
-
Attribution:SelfType of financial relationship:OtherIneligible company:CytomX TherapeuticsDate added:08/16/2023Date updated:08/16/2023
-
Attribution:SelfType of financial relationship:OtherIneligible company:AstraZeneca/MedImmuneDate added:08/16/2023Date updated:08/16/2023
-
Attribution:SelfType of financial relationship:OtherIneligible company:MerckDate added:08/16/2023Date updated:08/16/2023
-
Attribution:SelfType of financial relationship:OtherIneligible company:TakedaDate added:08/16/2023Date updated:08/16/2023
-
Attribution:SelfType of financial relationship:OtherIneligible company:AmgenDate added:08/16/2023Date updated:08/16/2023
-
Attribution:SelfType of financial relationship:OtherIneligible company:Janssen OncologyDate added:08/16/2023Date updated:08/16/2023
-
Attribution:SelfType of financial relationship:OtherIneligible company:NovartisDate added:08/16/2023Date updated:08/16/2023
-
Attribution:SelfType of financial relationship:OtherIneligible company:Bristol-Myers SquibbDate added:08/16/2023Date updated:08/16/2023
-
Attribution:SelfType of financial relationship:OtherIneligible company:BayerDate added:08/16/2023Date updated:08/16/2023
-
Attribution:SelfType of financial relationship:OtherIneligible company:incyteDate added:08/16/2023Date updated:08/16/2023